IIM
CTMX icon

INTECH Investment Management’s CytomX Therapeutics CTMX Stock Holding History

INTECH Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Buy
+30,434
New +$116K ﹤0.01% 1921

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

INTECH Investment Management's CTMX Position: Q2 2026 in Review

INTECH Investment Management opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 30,434 shares worth $114K. The stake represents ﹤0.01% of the portfolio and ranks #1921 among its holdings.

179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • INTECH Investment Management held 30,434 shares of CytomX Therapeutics worth $114K as of Q2 2026.
  • CytomX Therapeutics was a new INTECH Investment Management position in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1921 holding.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.